What is Digostics?
Digostics is at the forefront of revolutionizing diabetes screening and management through its advanced home testing platforms. The company specializes in enabling patients to conduct crucial tests, such as the oral glucose tolerance test (OGTT), with laboratory-grade accuracy from their residences. This patient-centric model is designed to bolster early detection of diabetes, including type 1, type 2, and gestational diabetes, thereby facilitating prompt clinical interventions and improving patient outcomes. By minimizing the need for traditional in-clinic visits, Digostics enhances accessibility and convenience for individuals at risk, while also providing valuable tools for healthcare providers and researchers.
How much funding has Digostics raised?
Digostics has raised a total of $675K across 1 funding round:
Other Financing Round
$675K
Other Financing Round (2025): $675K, investors not publicly disclosed
What's next for Digostics?
The recent major enterprise-level funding positions Digostics for substantial growth and expansion. This capital infusion is expected to fuel further development of their innovative home testing solutions, enhance market penetration, and potentially broaden their service offerings. The strategic nature of this investment suggests a strong belief in Digostics' business model and its capacity to disrupt traditional diagnostic pathways. Future initiatives will likely focus on scaling operations, forging new partnerships within the healthcare ecosystem, and continuing to refine their technology to meet the evolving needs of patients and clinicians in diabetes care.
See full Digostics company page
